Compare NUVL & VIPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | VIPS |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.7B |
| IPO Year | 2021 | 2012 |
| Metric | NUVL | VIPS |
|---|---|---|
| Price | $123.40 | $13.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $134.75 | $19.58 |
| AVG Volume (30 Days) | 2.5M | ★ 2.6M |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.79 |
| Revenue Next Year | $1,239.49 | $2.05 |
| P/E Ratio | ★ N/A | $9.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $13.44 |
| 52 Week High | $123.62 | $21.08 |
| Indicator | NUVL | VIPS |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 41.65 |
| Support Level | $97.71 | N/A |
| Resistance Level | N/A | $15.11 |
| Average True Range (ATR) | 4.37 | 0.47 |
| MACD | 1.97 | -0.05 |
| Stochastic Oscillator | 99.39 | 21.75 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.